BR112022024262A2 - Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april - Google Patents
Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a aprilInfo
- Publication number
- BR112022024262A2 BR112022024262A2 BR112022024262A BR112022024262A BR112022024262A2 BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2 BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- april
- methods
- iga nephropathy
- binding antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODOS DE TRATAMENTO DE NEFROPATIA POR IGA COM UM ANTICORPO DE LIGAÇÃO A APRIL. Formulação e uso de anticorpos que se ligam a APRIL humana para o tratamento de condições relacionadas à superprodução ou depósito de IgA, incluindo Nefropatia por IgA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062704831P | 2020-05-29 | 2020-05-29 | |
PCT/US2021/035011 WO2021243298A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating iga nephropathy with an april binding antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022024262A2 true BR112022024262A2 (pt) | 2023-02-23 |
Family
ID=78722933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022024262A BR112022024262A2 (pt) | 2020-05-29 | 2021-05-28 | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210379183A1 (pt) |
EP (1) | EP4157339A1 (pt) |
JP (1) | JP2023527563A (pt) |
KR (1) | KR20230017223A (pt) |
CN (1) | CN115996748A (pt) |
AU (1) | AU2021279035A1 (pt) |
BR (1) | BR112022024262A2 (pt) |
CA (1) | CA3179812A1 (pt) |
IL (1) | IL298370A (pt) |
MX (1) | MX2022014995A (pt) |
WO (1) | WO2021243298A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
WO2023212518A1 (en) | 2022-04-25 | 2023-11-02 | Visterra, Inc. | Antibody molecules to april and uses thereof |
WO2024092240A1 (en) | 2022-10-28 | 2024-05-02 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
WO2024099272A1 (zh) * | 2022-11-07 | 2024-05-16 | 信瑞诺医药(上海)有限公司 | 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
EA030313B1 (ru) * | 2007-03-27 | 2018-07-31 | Займодженетикс, Инк. | СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА |
SI2403528T1 (sl) * | 2009-03-02 | 2016-07-29 | Aduro Biotech Holdings, Europe B.V. | Protitelesa proti proliferacijo inducirajočemu ligandu (april) |
NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
UY36969A (es) * | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
HUE064655T2 (hu) * | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban |
CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
-
2021
- 2021-05-28 WO PCT/US2021/035011 patent/WO2021243298A1/en unknown
- 2021-05-28 MX MX2022014995A patent/MX2022014995A/es unknown
- 2021-05-28 CA CA3179812A patent/CA3179812A1/en active Pending
- 2021-05-28 KR KR1020227043773A patent/KR20230017223A/ko active Search and Examination
- 2021-05-28 JP JP2022573609A patent/JP2023527563A/ja active Pending
- 2021-05-28 US US17/334,590 patent/US20210379183A1/en active Pending
- 2021-05-28 EP EP21813022.7A patent/EP4157339A1/en active Pending
- 2021-05-28 CN CN202180046732.2A patent/CN115996748A/zh active Pending
- 2021-05-28 AU AU2021279035A patent/AU2021279035A1/en active Pending
- 2021-05-28 BR BR112022024262A patent/BR112022024262A2/pt unknown
- 2021-05-28 IL IL298370A patent/IL298370A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021243298A1 (en) | 2021-12-02 |
AU2021279035A1 (en) | 2023-02-02 |
MX2022014995A (es) | 2023-02-09 |
JP2023527563A (ja) | 2023-06-29 |
EP4157339A1 (en) | 2023-04-05 |
CA3179812A1 (en) | 2021-12-02 |
CN115996748A (zh) | 2023-04-21 |
US20210379183A1 (en) | 2021-12-09 |
KR20230017223A (ko) | 2023-02-03 |
IL298370A (en) | 2023-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
BR112021011431A2 (pt) | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit | |
BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
BR112019008426A2 (pt) | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo | |
AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
CR20150054A (es) | Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso | |
BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
BR112021013397A2 (pt) | Anticorpos anti-tigit | |
BR112019023898A2 (pt) | método para tratamento de câncer gástrico, uso de um anticorpo e composição | |
BR112021008873A8 (pt) | Formulação | |
BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas | |
ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
DOP2022000129A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
BR112018008900A2 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
CO2021015254A2 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos | |
ECSP21046332A (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso | |
CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
AR120117A2 (es) | Moléculas de unión a pd-1 y métodos de uso de las mismas | |
BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão |